WHO-led COVAX vaccine scheme agrees new supply deal with India's Serum
03/02/2021 13:38
GENEVA/LONDON, Feb 3 (Reuters) - India's Serum Institute
will supply 1.1 billion doses of COVID-19 vaccines developed by
AstraZeneca AZN.L and Novavax NVAX.O to the COVAX vaccine
scheme as part of a new long-term deal, head of the U.N.
Children's Fund said on Wednesday.
UNICEF chief Henrietta Fore said the shots would be
delivered over a number of years at the cost of about $3 per
dose for low- and middle-income countries.
They would be produced by Serum under a technology transfer
agreement, she said in a briefing.
The COVAX facility is co-led by GAVI, the World Health
Organization, the Coalition for Epidemic Preparedness
Innovations and UNICEF.
(Reporting by Stephanie Nebahay in Geneva and Kate Kelland in
London;
Writing by Josephine Mason; Editing by Toby Chopra)
((Josephine.Mason@thomsonreuters.com; +44 207 542 7695; Reuters
Messaging: josephine.mason.reuters.com@reuters.net))